- Home
- NEOV vs HURA Comparison
NEOV vs HURA Comparison
Compare NEOV & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- HURA
- Stock Information
- Founded
- NEOV 2018
- HURA 2009
- Country
- NEOV United States
- HURA United States
- Employees
- NEOV N/A
- HURA N/A
- Industry
- NEOV Industrial Machinery/Components
- HURA
- Sector
- NEOV Miscellaneous
- HURA
- Exchange
- NEOV Nasdaq
- HURA Nasdaq
- Market Cap
- NEOV 153.9M
- HURA 131.8M
- IPO Year
- NEOV N/A
- HURA N/A
- Fundamental
- Price
- NEOV $4.33
- HURA $2.40
- Analyst Decision
- NEOV Hold
- HURA Strong Buy
- Analyst Count
- NEOV 1
- HURA 2
- Target Price
- NEOV N/A
- HURA $11.50
- AVG Volume (30 Days)
- NEOV 335.8K
- HURA 174.9K
- Earning Date
- NEOV 11-07-2025
- HURA 11-13-2025
- Dividend Yield
- NEOV N/A
- HURA N/A
- EPS Growth
- NEOV N/A
- HURA N/A
- EPS
- NEOV N/A
- HURA N/A
- Revenue
- NEOV $8,426,835.00
- HURA N/A
- Revenue This Year
- NEOV $91.25
- HURA N/A
- Revenue Next Year
- NEOV $30.38
- HURA N/A
- P/E Ratio
- NEOV N/A
- HURA N/A
- Revenue Growth
- NEOV 218.59
- HURA N/A
- 52 Week Low
- NEOV $1.80
- HURA $1.80
- 52 Week High
- NEOV $6.19
- HURA $8.25
- Technical
- Relative Strength Index (RSI)
- NEOV 40.45
- HURA 43.36
- Support Level
- NEOV $5.30
- HURA $2.37
- Resistance Level
- NEOV $5.88
- HURA $2.61
- Average True Range (ATR)
- NEOV 0.54
- HURA 0.14
- MACD
- NEOV -0.14
- HURA -0.00
- Stochastic Oscillator
- NEOV 6.90
- HURA 20.63
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.